Researchers from the group at Uppsala University, led by Olof Eriksson, Associate Professor at Uppsala University, Senior PET Imaging Director at Antaros Medical, and Chief Scientific Officer at Antaros Tracer, will be presenting some exciting new research next week at the 25th International Symposium on Radiopharmaceutical Sciences (iSRS) in Honolulu, Hawaii.
There is increased interest in bi- and tri- modal incretin receptor agonists targeting glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP) and/or glucagon receptors for the treatment of type 2 diabetes (T2D) and obesity.
Investigating target occupancy in specific organs and tissues can help to build a better understanding of the drug’s efficacy. Positron Emission Tomography 8PET) imaging is a valuable tool for doing so, as tracers are being developed to target these same receptors. PhD student Amina Khalil will present work investigating target occupancy of novel bi- and tri- modal incretin receptor agonists using PET.
Gastric inhibitory peptide (GIP), also known as glucose-dependent insulinotropic polypeptide, receptors are a popular target for multi-agonistic drug candidates, yet the availability of in vivo biomarkers of activity at GIP receptors remains limited. This can make it challenging to measure target occupancy or engagement. Amina Khalil et al. evaluate a novel PET tracer, [68GA]GA-DOTA-GIP1234, which targets GIP receptors.
Find the details for these abstracts below, and make sure not to miss them at iSRS:
Title: Evaluation of tirzepatide and SAR441255 occupancy in pigs using PET imaging technique
Authors: Khalil A, Velikyan I, Bossart M, Wagner M, Eriksson O
Abstract number: 196
Friday May 26, 14:45-15:30 HST
Title: Introduction of a fatty acid chain modification to prolong the circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor (GIP)
Authors: Khalil A, Velikyan I, Hakhverdyan S, Cheung P, Bossart M, Wagner M, Eriksson O
Abstract number: 190
Friday May 26, 14:45-15:30 HST